Updated October 4, 2026
A CRO manages a medical device clinical trial across five stages: pre-trial planning, site selection and activation, patient enrollment and monitoring, data management and closeout, and post-market follow-up. A specialized CRO handles each stage on the sponsor's behalf, from the first design freeze checkpoint through study close.
What Makes a Medical Device Clinical Trial Different From a Drug Trial?
Medical device trials follow a different regulatory and operational logic than drug trials, and that difference shapes every decision a CRO makes. Sponsors new to medical equipment studies will find the distinctions affect everything from site selection to data structure. The most visible gap is structural: drug trials move through defined phases (I, II, III), while device trials rarely use that framework. Research by EClinCloud shows that 94.4% of device trial records list their phase as "NA" rather than using traditional drug phase labels. A CRO without device-specific experience will default to drug-trial workflows and create problems that slow submissions.
Randomization is another dividing line. Because many devices are implanted, operator-dependent, or impossible to blind, randomized controls are far less common than in drug research. EClinCloud data shows that randomized allocation is used in only 39.1% of industry medical device trial records. A device CRO must design monitoring plans, data collection tools, and statistical analysis strategies that fit this reality.
The regulatory pathway also differs. Drug sponsors file an Investigational New Drug (IND) application; device sponsors file an Investigational Device Exemption (IDE) under FDA 21 CFR Part 812. Data collected under ISO 14155, the international standard for Good Clinical Practice in medical device trials, must be structured to meet both that standard and FDA requirements. A CRO that understands both frameworks can draft protocols and case report forms that satisfy regulators on both sides without a full redesign late in the program.
Feasibility vs. Pivotal Trials: Which Stage Comes First?
Feasibility comes first. A feasibility study, also called an early feasibility study (EFS) or first-in-human (FIH) study, uses a small patient group to answer basic research questions: Can the device be used safely in humans? Does the procedure work as intended? Does the design need refinement before a larger study? These studies typically enroll fewer than 30 subjects and are not designed to produce statistically conclusive evidence of effectiveness. Their purpose is to generate the safety and usability data that informs the next step.
A pivotal trial follows once the device design is stable and the sponsor has enough early evidence to justify a larger commitment. The pivotal study is designed to demonstrate a reasonable assurance of safety and effectiveness for a marketing application, whether a 510(k), PMA, or De Novo request. Enrollment is larger, endpoints are pre-specified, and the protocol is designed to produce the primary evidence the FDA or a foreign regulator will evaluate. Pivotal trials are expensive and time-consuming, which is why sponsors who skip the feasibility stage and go straight to a pivotal design often face mid-trial protocol amendments or, worse, early termination.
The two stages are not always sequential in a rigid sense. Some sponsors run an EFS and a pivotal study in the same country under a single IDE. Others use OUS early clinical data, collected outside the United States under an IDE or a local ethics and regulatory approval, to reduce domestic enrollment burden before the pivotal phase begins. For a detailed look at how first-in-human studies are structured and executed, the first-in-human trials guide covers the full pathway from protocol design through regulatory submission.
How Does a CRO Manage Each Stage of a Medical Device Clinical Trial?
A device CRO's work is sequential but overlapping. The tasks below follow the order a sponsor encounters them, from the earliest planning decisions through study close.
Stage 1: Pre-trial planning and regulatory alignment
The CRO's first task is to confirm that the device has reached design freeze before any clinical protocol is drafted. Design freeze in a medical device program is the point at which the device's design specifications are locked and no further changes will be made before the study. Drafting a protocol against a device that is still changing wastes resources and risks a protocol amendment before the first patient is enrolled. Once design freeze is confirmed, the CRO conducts a regulatory gap analysis, maps the IDE or local regulatory pathway, and prepares or supports an FDA Pre-Submission (Pre-Sub) meeting request to align the protocol with agency expectations before submission.
Stage 2: Site selection and activation
Site selection involves identifying clinical sites with the patient population, device experience, and infrastructure to execute the protocol. This work falls under Navigating Regulatory Landscapes in Latin America when the program targets that region. The CRO evaluates sites against the protocol's inclusion and exclusion criteria, assesses investigator experience with the device category, and confirms that the site can meet enrollment timelines. Principal investigator (PI) identification follows site qualification. The CRO then manages ethics committee (EC) submissions, import permits for the investigational device, and site initiation visits before the first patient is screened.
Stage 3: Patient enrollment and monitoring
Enrollment is where most trials run into trouble (more on that in the next section). The CRO manages subject recruitment logistics, screens candidates against eligibility criteria, and tracks enrollment against the projected timeline. Monitoring visits, conducted according to a risk-based monitoring plan aligned with ISO 14155 and FDA 21 CFR 812, verify that the site is following the protocol, that data entries match source documents, and that adverse events are captured and reported correctly.
Stage 4: Data management and study closeout
As enrollment closes, the CRO runs data cleaning queries, resolves discrepancies between case report forms and source data, and prepares the clinical study report. Database lock requires that all outstanding queries are resolved and all adverse event narratives are complete. The CRO then compiles the clinical evidence package in the format required for the target submission, whether an IDE report, a PMA module, or a CE technical file.
Stage 5: Post-market clinical follow-up
Post-market clinical follow-up (PMCF) is not optional for many device classes. Regulators in the United States and across Latin America require sponsors to monitor long-term safety and performance after the device is cleared or approved. The CRO designs the PMCF protocol, identifies follow-up sites, and manages ongoing data collection and reporting against the approved plan.
What Are the Most Common Reasons a Medical Device Trial Fails?
Enrollment failure is the leading cause. According to MedDeviceGuide's 2026 analysis of 2,422 studies, enrollment and accrual failure accounts for 39.4% of device trial terminations. Sites that looked viable during qualification run out of eligible patients, competing trials absorb the same population, or investigators lose capacity mid-study. The result is a trial that stalls, burns through budget, and either terminates early or delivers underpowered data that cannot support a submission.
The overall termination rate for device studies is not trivial. MedDeviceGuide's analysis of 63,059 trials found an early termination rate of 9.76%. That means roughly one in ten device trials does not reach its primary endpoint. Sponsors who underestimate enrollment complexity, particularly for devices targeting narrow indications or requiring specialized implanting surgeons, carry most of that risk.
A CRO with a pre-qualified site network directly reduces this exposure. When a CRO has already vetted sites for patient volume, investigator experience, and operational capacity before a trial opens, it can match the protocol's enrollment targets to realistic site throughput. If a site underperforms, the CRO can activate a backup site without waiting to restart the qualification process from scratch.
Other causes of termination include protocol design problems, funding interruptions, and adverse safety signals. Protocol issues, such as inclusion criteria that are too narrow or endpoints that are difficult to measure in a device context, often trace back to insufficient pre-trial planning. A CRO that engages early, before design freeze and before the IDE is drafted, catches these problems when they are still cheap to fix.
How Do Digital Tools and Decentralized Approaches Support Modern Device Trials?
Digital tools are changing how device trials collect data and recruit patients, but they do not reduce cost uniformly. A 2025 survey by ISR Reports found that 65% of professionals believe decentralized clinical trials are more costly than traditional models. Sponsors should evaluate decentralization on a per-program basis rather than assuming it will compress budgets.
Where digital infrastructure adds clear value is in data quality and recruitment speed. AI-driven recruitment platforms can screen patient databases against inclusion and exclusion criteria faster than manual chart review, reducing the time between site activation and first patient enrolled. Remote monitoring tools allow a CRO to review source data and flag discrepancies between site visits, which shortens the data cleaning cycle at closeout. Electronic case report forms with built-in logic checks catch entry errors at the point of data entry rather than weeks later during a monitoring visit.
Milo Healthcare offers a cloud-based platform covering study setup, AI-driven patient recruitment, voice-to-text documentation, and video EMR integration. Note that per UK government filings, Milo Healthcare Ltd was dissolved in August 2025, so sponsors evaluating this platform should confirm its current operational status before committing to it.
For device trials in Latin America, remote monitoring is particularly practical. Sites in Panama, Colombia, and Chile may be hundreds of miles from a sponsor's home office. A CRO that combines on-site monitoring visits with remote data review can maintain oversight frequency without a proportional increase in travel costs. The key is building the remote monitoring plan into the protocol and the monitoring agreement before the trial opens, not retrofitting it after enrollment begins.
How Do You Choose a CRO With Medical Device Trial Expertise?
The global market for medical device clinical trials was valued at USD 16,630.7 million in 2024, according to Grand View Research. That scale means a large number of CROs compete for device trial work, including many whose core competency is drug development. Choosing the wrong one costs time the sponsor's financial runway cannot absorb.
Ask these questions before signing a work order:
-
Does the CRO have direct IDE experience? An IDE submission requires device-specific regulatory knowledge, including the FDA's expectations for risk analysis, protocol design, and investigator qualifications. Ask for examples of IDE submissions the CRO has prepared and whether any resulted in a Pre-Sub meeting with FDA.
-
Is the CRO fluent in ISO 14155? ISO 14155 governs Good Clinical Practice for medical device trials. A CRO that defaults to ICH E6 (the drug-trial GCP standard) will produce monitoring plans and case report forms that need to be rebuilt before a device submission.
-
What does the site network actually look like? Pre-qualified sites reduce enrollment risk. Ask how many sites the CRO has activated in the past 24 months, in which therapeutic areas, and what their average time from ethics submission to first patient enrolled was.
-
Can the CRO support both feasibility and pivotal stages? Some CROs specialize in early-phase work and hand off pivotal execution to a larger partner. If your program runs from EFS through PMA, confirm the CRO can manage both without a transition that disrupts data continuity.
-
Does the CRO have in-country regulatory staff for your target geography? In Latin America, regulatory requirements vary by country. A CRO with local staff who know INVIMA in Colombia, COFEPRIS in Mexico, or ANMAT in Argentina will move faster than one managing those submissions remotely from the United States.
For a structured comparison of CRO capabilities across these dimensions, Contract Research Organization Companies: How to Compare Them walks through the evaluation criteria in detail.
How bioaccess® Manages Medical Device Clinical Trials in Latin America
bioaccess® is a Miami-headquartered CRO that manages medical device clinical trials for MedTech, biopharma, and radiopharma sponsors across Latin America. Its work is structured around two service lines, each designed to address a distinct stage of a sponsor's clinical and commercial timeline.
The FIH-12™ program is a nine-workstream, 12-month engagement built for sponsors entering human studies. It covers FDA Pre-Sub and IDE/IND pathway alignment, protocol development, site activation, patient enrollment, data management, and delivery of a submission-ready clinical evidence package. The program is designed so that data collected under ISO 14155 and structured per FDA 21 CFR 812 can be used directly in U.S. IDE and IND submissions, removing the need for a data reformatting cycle before the sponsor files. For a detailed look at how FDA Pre-Sub Meeting: How to Get the Most From Your Q-Sub Response fits into pre-trial planning, that guide covers the process step by step.
For sponsors whose devices are already FDA-cleared (510(k) or PMA) or CE-marked, the LATAM Launch Subscription handles in-country holder and Importer of Record registration across 19 markets, covering ANVISA in Brazil, INVIMA in Colombia, COFEPRIS in Mexico, ANMAT in Argentina, ISP in Chile, DIGEMID in Peru, and other regional regulators. Sponsors entering new markets can also refer to How to register a medical device in Uruguay with MSP (single Local Holder) and How to register a medical device in the Dominican Republic with DIGEMAPS for country-specific registration detail.
For sponsors evaluating first-in-human execution in Latin America, the first-in-human trials guide outlines the full pathway from protocol design through regulatory submission. This article was written by Tely Publisher.
Prices and plan limits verified as of October 2026.
FAQs
What is a medical device clinical trial?
A medical device clinical trial is a study conducted in human subjects to evaluate a device's safety and performance. Unlike drug trials, device trials rarely follow the traditional phase I through III structure. Instead, they move from early feasibility or first-in-human studies through pivotal trials designed to support a marketing application, such as a PMA or 510(k) submission to the FDA.
What regulatory standards govern medical device trials?
FDA 21 CFR Part 812 governs Investigational Device Exemptions in the United States. ISO 14155 covers Good Clinical Practice for medical device trials internationally. A CRO must structure protocols, case report forms, monitoring plans, and clinical study reports to satisfy both frameworks when the sponsor intends to use the data for a U.S. submission.
What is design freeze in the context of a medical device trial?
Design freeze is the point at which a device's design specifications are locked and no further changes are made before the clinical study begins. A CRO should confirm design freeze before drafting the clinical protocol, because any subsequent design change can invalidate the protocol and require an amendment before the first patient is enrolled.
How long does a medical device clinical trial typically take?
Timeline depends on trial type, indication, and geography. An early feasibility study with fewer than 30 subjects can complete enrollment in six to twelve months if site activation is efficient. A pivotal trial supporting a PMA typically runs two to four years from IDE submission through database lock. In Latin America, ethics and regulatory approvals in Panama, El Salvador, Chile, and the Dominican Republic are typically observed in 30 to 90 days, which compresses the pre-enrollment phase compared to some other markets.
What is post-market clinical follow-up (PMCF) and when is it required?
Post-market clinical follow-up (PMCF) is a program that monitors device safety and performance after the device is cleared or approved and in commercial use. Many device classes require it under both U.S. and Latin American regulations. PMCF data is used to detect long-term safety signals, support labeling updates, and satisfy ongoing regulatory obligations. A CRO designs the PMCF protocol, identifies follow-up sites, and manages data collection and reporting against the approved plan.
Conclusion
When evaluating a CRO, focus on three things: direct IDE submission experience, a pre-qualified site network in your target geography, and in-country regulatory staff who know the specific agencies you will file with. A CRO that engages before design freeze, maintains a pre-qualified site network, and can carry a program from first-in-human through data closeout removes the handoff risk that stalls most programs.